Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-Squamous Non Small Cell Lung Cancer (NSCLC).
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms TASTE
- 01 Apr 2024 Results assessing the prognostic significance of STK11/LKB1 alterations in localized non-squamous non-small cell lung carcinoma , published in the Lung Cancer
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.